Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Topics - Archive

Publication of Q3 2016 Results
Publication of Q3 2016 Results
“We had a good third quarter and are lifting our guidance for the full year. We have made good progress with the execution of our strategy. We have advanced our pharmaceutical pipeline and are realizing the cost synergies from the acquisition of Sigma-Aldrich faster than planned. In the course of the year, we have lowered our debt from the acquisition by € 1 billion.” Stefan Oschmann, CEO and Chairman of the Executive Board
 
Access to Medicine Index 2016
Access to Medicine Index 2016
The Access to Medicine Foundation has set itself the objective of improving access to health in low- and middle-income countries. To this end, it benchmarks the activities and initiative of the world’s 20 largest pharmaceutical companies in the Access to Medicine Index. In the recently published 2016 index, our company ranks among the top five.
 
Investing in China
Investing in China
By 2018, China will be the world’s second-largest pharmaceutical market. That’s why we are boosting our investments in China. In Nantong, we have inaugurated a new pharmaceutical manufacturing site to produce medicines on China’s Essential Drugs List for the treatment of diabetes, cardiovascular disease and thyroid disorders. And with the planned construction of a Life Science production facility also at the Nantong site, we want to offer products for China's pharmaceutical and biopharmaceutical industries.
 
Our commitment to Africa
Our commitment to Africa
Africa – A multifaceted continent. Our activities there are equally multifaceted. Starting with our joint efforts with WHO to eliminate the tropical disease schistosomiasis and information events for healthcare professionals up to the establishment of our own business offices to get closer to our customers.
 
The car of the future
The car of the future
How can we have less congested roads, fewer accidents, cleaner air, relaxed driving, and more free space in overcrowded cities and still remain mobile? The cars of tomorrow are to meet these expectations by using the possibilities of autonomous driving, alternative engine types and digital connectivity. Our high-tech materials are also being used to build the car of the future. That’s why we are focusing on the future of mobility at our “Displaying Futures” symposium. The theme of this year’s symposium is “Driving Forces”.
 
New OLED plant up and running
New OLED plant up and running
Wall-sized displays at airports or train stations that provide sharp images from any viewing angle? Rollable displays for video walls, or flexible and bendable smartphones? A vision that can soon become reality thanks to OLED technology. To take part in these developments and to further strengthen our market position in the OLED materials business, we have commissioned a new OLED materials production plant. 
 
ASCO 2016
ASCO 2016
The annual meeting of the American Society of Clinical Oncology (ASCO – June 3-6, 2016, Chicago) features research on our compounds across a broad range of cancers. This includes data on avelumab, our late-stage investigational immuno-therapy, that is being developed in collaboration with Pfizer.
 
Liquid crystals – not only for displays
Liquid crystals – not only for displays
Windows that automatically darken and eliminate the need for blinds? Our liquid crystal technology makes it possible. So far, their main uses have been in television displays and smartphones. But in the future,  we will produce modules for liquid crystal windows. We’re investing € 15 million in a production unit for switchable glass modules featuring LC technology.
 
Second-quarter results 2016
Strong second quarter
"We again achieved everything we aimed for in the second quarter. That applies to both the Sigma-Aldrich integration and the development of new medicines," said Stefan Oschmann, CEO and Chairman of our Executive Board. "Strong demand for our products and dynamic market developments gave our Healthcare and Life Science businesses additional tailwinds. Since particularly in Healthcare our performance in the second quarter was so good, we have decided to lift our forecast for the full year."
 
Strenghtening our U.S. presence
Strenghtening our U.S. presence
We are investing $115 million in a new life science campus in the Boston area, one of the most important science and technology hubs in the world. The new campus will serve as a premier global customer destination, housing a state-of-the-art exploratory environment where our scientists and engineers work together with customers to help solve their toughest life science challenges.
 
Cladribine tablets: Marketing authorization application
Cladribine tablets: Marketing authorization application
Darmstadt, Germany, July 18, 2016 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product Cladribine Tablets for the treatment of relapsing - remitting multiple sclerosis (MS).
 
Nigeria Receives Record Praziquantel Donation
Nigeria Receives Record Praziquantel Donation
Geneva, Switzerland, May 24, 2016 – Merck KGaA, Darmstadt, Germany, announced today that the largest single delivery of praziquantel tablets in the history of our Praziquantel Donation Program recently arrived in Abuja, the capital of Nigeria. The West African country has received around 34 million tablets for mass distribution to school children.
 
First quarter results 2016
First quarter results 2016
“We started off 2016 well and have grown profitably. The integration of Sigma-Aldrich is progressing quickly and we are also right on target with our debt reduction,” said Stefan Oschmann, CEOof our company.
 
Full-year results 2015
Strong Finish to 2015
Darmstadt, Germany, March 8, 2015 – Merck KGaA, Darmstadt, Germany, reported record results for 2015, emerging stronger from the transformation process that started in 2007. Net sales and EBITDA pre exceptionals were higher than ever before in the company’s history of nearly 350 years.
 
Merck KGaA, Darmstadt, Germany, Confident for 2016
Merck KGaA, Darmstadt, Germany, Confident for 2016
Darmstadt, Germany, December 10, 2015 – Merck KGaA, Darmstadt, Germany informed analysts and investors at its 2015 Capital Market Day about the strategic priorities that will influence its operating result in 2016.
 
Merck KGaA, Darmstadt, Germany, Counts on Africa for Growth
Merck KGaA, Darmstadt, Germany, Counts on Africa for Growth
Darmstadt, Germany, and Johannesburg, South Africa, November 20, 2015 – Merck KGaA, Darmstadt, Germany announced today that it plans to considerably expand its presence on the African continent over the next five years and is counting on the region’s entrepreneurial spirit and innovation power for growth.
 
Merck KGaA, Darmstadt, Germany, Completes Sigma-Aldrich Acquisition
Merck KGaA, Darmstadt, Germany, Completes Sigma-Aldrich Acquisition
Darmstadt, Germany, November 18, 2015 – Merck KGaA, Darmstadt, Germany, announced the completion of its $ 17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $ 130 billion global industry to help solve the toughest problems in life science.
 
Publication of business results 3rd quarter 2015
Third-Quarter Earnings Jump
Darmstadt, Germany, November 12, 2015 – "Our organic growth in all three business sectors and all regions shows that our strategy is bearing fruit. We are also well-positioned for future growth," said Karl-Ludwig Kley, CEO of our company. "The fact that we are lifting the forecast for the current full year is due to the good operational performance of our businesses as well as to the imminent acquisition of Sigma-Aldrich."
 
Branding
Merck KGaA, Darmstadt, Germany, launched new branding
Darmstadt, Germany, October 14, 2015 – Merck KGaA, Darmstadt, Germany, announced the relaunch of its visual identity. The fundamental revision of the visual appearance as well as the introduction of new logos for its US businesses EMD Serono, EMD Millipore and EMD Performance Materials reflect the transformation into a global science and technology company.
 
Merck KGaA, Darmstadt, Germany Opens Innovation Center
Merck KGaA, Darmstadt, Germany Opens Innovation Center
Merck KGaA, Darmstadt, Germany today opened its Innovation Center in Darmstadt, thus establishing a new platform for innovations from around the world and from the Rhine-Main region.
 
Merck in India
Our company in India
We have opened new headquarter offices in Mumbai recently, the inauguration was attended by Belén Garijo and Bernd Reckmann, both Members of the Executive Board of Merck KGaA, Darmstadt, Germany. Our previously company offices in Mumbai were spread over three locations.
 
Publication of the Results of Q2 2015
Results of the second-quarter of 2015
Darmstadt, Germany, August 6, 2015  – Merck KGaA, Darmstadt, Germany, today announced renewed strong sales growth, amounting to 14.4% in the second quarter of 2015. EBITDA pre exceptionals also rose by 6.3%. Merck KGaA, Darmstadt, Germany, thus continued on its growth course in the first half of 2015.
 
Growing presence – based on innovation
Growing presence – based on innovation
We are acquiring Qlight Nanotech Ltd., Jerusalem, Israel. “The acquisition of Qlight Nanotech perfectly fits into our innovation strategy as innovations are our lifeblood,” said Karl-Ludwig Kley, CEO and Chairman of the Executive Board of Merck KGaA, Darmstadt, Germany.
 
Merck KGaA, Darmstadt, Germany Invests € 30 Million in New OLED Production Plant in Darmstadt
Merck KGaA, Darmstadt, Germany Invests € 30 Million in New OLED Production Plant in Darmstadt
Starting in July 2016, materials for modern flat screens and lighting systems will be produced at a new OLED production plant. Merck KGaA, Darmstadt, Germany, is investing around 30 million euros in the new building at its headquarters in Darmstadt.
 
Taking Science Further Faster
Taking Science Further Faster
EMD Millipore has introduced the Mobius 2000 Liter Single-Use Bioreactor at this year’s ACHEMA in Frankfurt to help customers optimize their upstream processes. Bioreactors are used to grow microorganisms or cells in an ideal environment. 
 
Biopharma at Asco 2015 - Welcoming Collaboration, Driving Innovation
Merck KGaA, Darmstadt, Germany, at Asco 2015 - Welcoming Collaboration, Driving Innovation
Before the world’s most renowned meeting of oncology experts Asco starts in Chicago May 29 we have collected relevant information here - including to new websites and a registration for the press event taking place May 31st in Chicago.
 
Merck KGaA, Darmstadt, Germany, Starts 2015 with a Solid First Quarter
Merck KGaA, Darmstadt, Germany Starts a Challenging 2015 with a Solid First Quarter
“We are pleased that all three business sectors grew despite a challenging environment,” said Karl-Ludwig Kley, CEO of Merck KGaA, Darmstadt, Germany. “We continue to expect slight organic sales growth for the full year as well.”
 
Merck KGaA, Darmstadt, Germany supports schistosomiasis education in Mozambique
Merck KGaA, Darmstadt, Germany supports schistosomiasis education in Mozambique
In Namaacha, together with German Bundesrat President Volker Bouffier, Executive Board member Kai Beckmann presented to Mozambique’s Deputy Health Minister Dr. Mouzinho Saíde 20,000 brochures aimed at educating children on the causes of the tropical worm disease.
 
Publication of business results for the full year 2014
Merck KGaA, Darmstadt, Germany, Finishes Year of Key Strategic Moves with Record Figures
Darmstadt, Germany, March 3, 2015 – "In 2014 we have laid the foundations for future growth,” said Karl-Ludwig Kley, Chairman of the Executive Board. “The company is transforming into a highly specialized, global technology company with the goal to improve the lives of patients and customers.”
 
Consumer Health
Trends, Challenges and Innovation in Consumer Health: Evolution or Revolution?
Consumer Health Division Sparks Debate on the Future of the OTC Sector
November 28, 2014 – Our Consumer Health division hosted a top level debate on key future aspects of the OTC sector, in London. Featuring contributions from leading analysts, professional representatives and patient groups, the event combined the experience and views of our Consumer Health’s senior management team with external perspectives on the major pressures and influences facing the industry. 
 
Access to Medicine
Merck KGaA, Darmstadt, Germany, Advances to Sixth Place in the 2014 Access to Medicine Index
Darmstadt, Germany, November 18, 2014 – Merck KGaA, Darmstadt, Germany, announced today that it now ranks sixth in the Access to Medicine Index published yesterday by the Access to Medicine Foundation.
 
Global Strategic Alliance with Pfizer
Global Strategic Alliance with Pfizer
November 17, 2014 – Merck KGaA, Darmstadt, Germany, and Pfizer entered into a global agreement to co-develop and co-commercialize our investigational anti-PD-L1 antibody as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.
 
Publication of business results for 3rd Quarter 2014
Publication of business results for 3rd Quarter 2014
November 13, 2014 – Merck KGaA, Darmstadt, Germany, delivered strong sales growth of 9.3%, reporting sales of € 2.9 billion in the third quarter of 2014 (Q3 2013: € 2.7 billion). Owing to the good business performance in the first nine months and the very good organic sales growth in the third quarter, Merck KGaA, Darmstadt, Germany, is assuming slight organic sales growth for the full year 2014.
 
Displaying Futures
Displaying Futures – How displays influence architecture
November 5, 2014 – Merck KGaA, Darmstadt, Germany, is holding its “Displaying Futures”’ symposium in Shanghai, China on November 6, 2014. Focusing on the theme “Building Innovation – Displaying Architecture”, experts will discuss questions concerning the impact of innovative display solutions on architecture as well as the life of the people therein.
 
Acquisition of Sigma-Aldrich
Acquisition of Sigma-Aldrich
September 22, 2014 – Merck KGaA, Darmstadt, Germany, and Sigma-Aldrich, one of the leading US-based life science and technology companies, announced that they have entered into a definitive agreement under which Merck KGaA, Darmstadt, Germany, will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion) in cash, establishing one of the leading players in the $130 billion global life science industry.
 
Investor & Analyst Day on Biopharmaceuticals 2014
Investor & Analyst Day on Biopharmaceuticals 2014
September 18, 2014 – Our biopharmaceutical business is well on track. This is reflected for example by the successful execution of growth initiatives and by progress in the pipeline. This progress can be seen particularly in Immuno-Oncology, among others. Additionally Merck KGaA, Darmstadt, Germany, plans to step up investments in its Biosimilars unit next year.
 
Our Headquarters Starts Taking Shape
New Headquarters Starts Taking Shape
September 1, 2014 – The expansion of the Headquarters in Darmstadt into a contemporary global headquarters announced at the end of 2013 is clearly taking shape. A groundbreaking ceremony marked the start of construction on a modular Innovation Center at the Darmstadt site.
 
Organic Growth in all Four Businesses in Second Quarter
Organic Growth in all Four Businesses in Second Quarter
August 13, 2014 – Merck KGaA, Darmstadt, Germany, generated organic sales growth of 3.4% in the second quarter of 2014. In addition, the company reported an acquisition-related sales increase of 3.0%, which was countered by negative foreign exchange effects of -4.5%.
 
New Energy Station Supports Energy Revolution in Germany
New Energy Station Supports Energy Revolution in Germany
July 28, 2014 – The Chairman of the Executive Board, Karl-Ludwig Kley, and German Federal Economics Minister, Sigmar Gabriel, have commissioned a new co-generation plant, which will allow Merck KGaA, Darmstadt, Germany, to produce even more of its own electricity, heating and cooling for its Darmstadt site. With the new plant, the company is contributing not only to the energy revolution in Germany, but also to the global fight against climate change.
 
Merck KGaA, Darmstadt, Germany, and China
Merck KGaA, Darmstadt, Germany, and China
July 23, 2014 – Our Executive Board met in Shanghai, a month before the groundbreaking of its new pharmaceutical plant in Nantong, which from 2017 will be the Group’s second-largest pharmaceutical manufacturing facility globally. Merck KGaA, Darmstadt, Germany, currently employs more than 2,000 people at over 40 sites in China. In total, we have committed more than € 100 million to investments in China over the past three years.
 
We Achieve Profitable Organic Growth in the First Quarter
Publication of Business Results for Q1 2014
May 15, 2014 – Merck KGaA, Darmstadt, Germany, achieved organic sales growth of 3.7% in the first quarter of 2014. This was, however, more than offset by negative foreign exchange effects of 5.4%. Overall, sales slipped slightly by around € 46 million in the first quarter of 2014 to € 2.6 billion (Q1 2013: € 2.7 billion).
 
World Health Day: Focus on fighting schistosomiasis
World Health Day: Focus on Fighting Schistosomiasis
April 7, 2014 – Vector-borne diseases are the focal topic of World Health Day on April 7 this year. These are a group of diseases that are transmitted by vectors, i.e. living organisms such as mosquitoes, flies or ticks. Schistosomiasis, which is caused by worms, is also a vector-borne disease. Merck KGaA, Darmstadt, Germany, intends to expand its commitment to the fight against schistosomiasis tenfold.
 
.
Publication of business results for the full year 2013
March 6, 2014 – Merck KGaA, Darmstadt, Germany, announced strong full-year results and the achievement of its objectives for 2013 despite a challenging market environment. The company reported solid organic sales growth of 4.2 percent to € 10.7 billion. EBITDA pre one-time items increased by 9.7 percent to the record level of € 3.25 billion. The EBITDA pre margin rose by nearly three percentage points from 27.6 percent to 30.4 percent.
 
Merck KGaA, Darmstadt, Germany, Invests in Research Partnerships in Israel to Boost Innovation
We Invest in Research Partnerships in Israel to Boost Innovation
November 26, 2013 – Merck KGaA, Darmstadt, Germany, is increasingly counting on partnerships with Israeli biotech companies, as demonstrated by its cooperation with Metabomed, which joined the Israel Bioincubator. Merck KGaA, Darmstadt, Germany, is already cooperating with multiple Israeli start-up companies such as Qlight Nanotech, as well as research institutes such as the Weizmann Institute of Science as it seeks innovations that could become the basis for future products.
 
What does diversity have to do with innovation?
What does Diversity have to do with Innovation?
November 20, 2013 – "Not only do we want to sponsor diversity; we also need to foster it," says Belén Garijo, Chief Executive Officer of EMD Serono, our biopharmaceutical division. Through various initiatives, Merck KGaA, Darmstadt, Germany, is attempting to leverage the innovative potential of its increasingly heterogeneous workforce.
 
Merck KGaA, Darmstadt, Germany, in China
Merck KGaA, Darmstadt, Germany, in China
November 15, 2013 – Merck KGaA, Darmstadt, Germany, has been operating in China for 80 years now. The company is constantly expanding its presence in China, which is one of our eight strategic countries. Currently, Merck KGaA, Darmstadt, Germany, is represented in the pharmaceutical, chemical and life science sectors of the rapidly growing Chinese market.
 
Publication of business results for Q3 2013
Publication of Business Results for Q3 2013
November 14, 2013 – "This repeatedly strong result illustrates once again that we are on track with the transformation of our company. Merck KGaA, Darmstadt, Germany, is already stronger today and more profitable than when it started the change process a few years ago,” said Karl-Ludwig Kley, Chairman of the Executive Board. In the third quarter 2013 our company continued its solid business performance in a challenging market environment.
 
Second-quarter results 2013
Second-quarter Results 2013
August 6, 2013 – “Our solid business performance continued into the second quarter of 2013, with total revenues increasing organically by 3% even in a more difficult market environment. Our ‘Fit for 2018’ program is producing excellent results with the second-quarter EBITDA pre one-time items up 11%,” said Karl-Ludwig Kley, Chairman of the Executive Board.
 

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 

FOR MEDIA INQUIRIES, CONTACT

Media Team
POSTAL ADDRESS 
Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250 
64293 Darmstadt 
Germany
Tel.: +49 6151 72-5000
Fax: +49 6151 72-3138